Control Arm (arm B) – standard of care: atezolizumab plus bevacizumab
toxicity
DISEASE PROGRESSION
In arm B, patients will receive accordingly to standard of care: atezolizumab at fixed dose of 1200 mg IV infusion and bevacizumab at fixed dose of 15 mg/kg IV infusion since Day 1, every 3 weeks, until disease progression or unacceptable toxicity or maximum 2 years. Beyond the 2-year study period, and in the absence of disease progression or unacceptable toxicity, we recommend that investigators continue atezolizumab-bevacizumab treatment as part of standard practice.